Key Transdermal Patch Using Cannabidiol-Loaded Nanocarriers with Better Pharmacokinetics in vivo
DOI: https://doi.org/10.2147/ijn.s455032
IF: 7.033
2024-05-17
International Journal of Nanomedicine
Abstract:Po-Cheng Chu, 1, 2 Man-Hua Liao, 3 Mao-Gu Liu, 1 Cun-Zhao Li, 2 Ping-Shan Lai 1 1 Department of Chemistry, National Chung Hsing University, Taichung, Taiwan; 2 Basic Research and Development Department, Powin Biomedical Co. Ltd., Taichung, Taiwan; 3 Graduate Institute of Biotechnology, National Chung Hsing University, Taichung, Taiwan Correspondence: Ping-Shan Lai, Department of Chemistry, National Chung Hsing University, No. 145, Xingda Road, Taichung, 402, Taiwan, Tel +886-4-22840411 Ext 428, Fax +886-4-22862547, Email Purpose: Cannabidiol (CBD) is a promising therapeutic drug with low addictive potential and a favorable safety profile. However, CBD did face certain challenges, including poor solubility in water and low oral bioavailability. To harness the potential of CBD by combining it with a transdermal drug delivery system (TDDS). This innovative approach sought to develop a transdermal patch dosage form with micellar vesicular nanocarriers to enhance the bioavailability of CBD, leading to improved therapeutic outcomes. Methods: A skin-penetrating micellar vesicular nanocarriers, prepared using nano emulsion method, cannabidiol loaded transdermal nanocarriers-12 (CTD-12) was presented with a small particle size, high encapsulation efficiency, and a drug-loaded ratio for CBD. The skin permeation ability used Strat-MTM membrane with a transdermal diffusion system to evaluate the CTD and patch of CTD-12 (PCTD-12) within 24 hrs. PCTD-12 was used in a preliminary pharmacokinetic study in rats to demonstrate the potential of the developed transdermal nanocarrier drug patch for future applications. Results: In the transdermal application of CTD-12, the relative bioavailability of the formulation was 3.68 ± 0.17-fold greater than in the free CBD application. Moreover, PCTD-12 indicated 2.46 ± 0.18-fold higher relative bioavailability comparing with free CBD patch in the ex vivo evaluation. Most importantly, in the pharmacokinetics of PCTD-12, the relative bioavailability of PCTD-12 was 9.47 ± 0.88-fold higher than in the oral application. Conclusion: CTD-12, a transdermal nanocarrier, represents a promising approach for CBD delivery, suggesting its potential as an effective transdermal dosage form. Keywords: cannabidiol, pharmacokinetics, transdermal, nano emulsion, drug patch, nanocarrier Graphical Cannabidiol (CBD) is a promising therapeutic drug with low addictive potential and a favorable safety profile. 1 Studies have shown that CBD does not exhibit the psychoactive effects commonly associated with tetrahydrocannabinol (THC), making it a safer option for therapeutic use. Its non-addictive nature makes it an appealing choice for patients seeking effective treatments without the risk of dependency. Clinical studies have indicated that CBD holds promise for potential applications in treating various chronic diseases and neurological conditions, with possible positive effects for managing conditions such as epilepsy, 2,3 Alzheimer's disease, 4 Parkinson's disease, 5,6 sleep disorders, 7,8 depression and psychotic disorders, 9 anxiety, 9 schizophrenia, 10 and post-traumatic stress disorder. 11 However, CBD has faced certain challenges affecting its administration and efficacy. One challenge has concerned its hydrophobic nature, with poor water solubility posing difficulties in formulating CBD into aqueous solutions, limiting its options for oral delivery. 12,13 Another disadvantage has been the low oral bioavailability of CBD. CBD undergoes extensive first-pass metabolism in the liver when taken orally, significantly reducing its bioavailability. 14,15 Hence, only a fraction of the orally administered CBD reaches the systemic circulation in an active form, reducing its therapeutic effectiveness. Despite these drawbacks, ongoing research has aimed to develop innovative strategies to improve CBD's solubility and oral bioavailability, including nano formulations and other delivery systems. These advancements may enhance the effectiveness of CBD as a therapeutic drug and expand its applications in various medical conditions. In the pharmaceutical industry, oral intake remains the most preferred method of drug administration due to its advantages, such as the availability of various dosage forms, painless administration, the feasibility of solid formulations, self-administration, and patient compliance. 16–18 However, oral drug delivery also has disadvantages, including drug stability in the gastrointestinal tract, first-pass metabolism, poor water solubility, and limited absorption through physiologica -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology